Free Trial

Quest PharmaTech Q1 2025 Earnings Report

Quest PharmaTech logo
C$0.03 0.00 (0.00%)
As of 04/1/2025 03:55 PM Eastern

Quest PharmaTech EPS Results

Actual EPS
-C$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Quest PharmaTech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quest PharmaTech Announcement Details

Quarter
Q1 2025
Time
N/A

Conference Call Resources

Remove Ads

Quest PharmaTech Earnings Headlines

Quest PharmaTech Inc (QPT)
America’s Retirement Accounts Are at Risk—Here’s Why
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
Quest PharmaTech Announces Results from AGM
See More Quest PharmaTech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quest PharmaTech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quest PharmaTech and other key companies, straight to your email.

About Quest PharmaTech

Quest PharmaTech (CVE:QPT), a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.

View Quest PharmaTech Profile

More Earnings Resources from MarketBeat